J 2020

Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience

SANDECKÁ, Viera, Zdeněk ADAM, Marta KREJČÍ, Martin ŠTORK, Zdeněk ŘEHÁK et. al.

Basic information

Original name

Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience

Authors

SANDECKÁ, Viera (703 Slovakia), Zdeněk ADAM (203 Czech Republic), Marta KREJČÍ (203 Czech Republic), Martin ŠTORK (203 Czech Republic, guarantor), Zdeněk ŘEHÁK (203 Czech Republic), Renata KOUKALOVÁ (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Zdeněk KRÁL (203 Czech Republic), Jiří MAYER (203 Czech Republic) and Luděk POUR (203 Czech Republic)

Edition

Neoplasma, Bratislava, Slovenská akademie vied, 2020, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.575

RIV identification code

RIV/00216224:14110/20:00116304

Organization unit

Faculty of Medicine

UT WoS

000557901000025

Keywords in English

monoclonal gammopathy; cancer; multiple myeloma; PET/CT

Tags

International impact, Reviewed
Změněno: 1/9/2020 09:08, Mgr. Tereza Miškechová

Abstract

V originále

Monoclonal gammopathy of undetermined significance (MGUS) is a known precursor of more serious cancers, such as multiple myeloma (MM), Waldenstrom macroglobulinemia (MW) and other lymphoproliferative disorders. Using 18F-FDG PET/CT, we aimed to evaluate its benefit in early detection of various accompanying disorders and illnesses in MGUS patients. We prospectively analyzed the diagnostic relevance of 18F-FDG PET/CT in 390 newly diagnosed MGUS patients. On 18F-FDG PET/CT scans, the presence of focal or diffuse areas of detectable increased tracer uptake was recorded in 37 (9.5%) MGUS patients. The most frequent pathology was lymphadenopathy (3.8%), followed by thyroid diseases (2.1%), rheumatic diseases (1.8%), and other solid malignancies (1.5%). These results have major implications for confirmed associations of MGUS with numerous malignant and non-malignant disorders. We believe that 18F-FDG PET/CT imaging in newly diagnosed MGUS patients may be useful in early detection of other serious pathologies, not only in predicting progression of MGUS to active MM, and should be strongly recommended if available.